Sivapriya Kirubakaran

Dr. Sivapriya Kirubakaran did her Ph.D (Organic chemistry) from IISc, Bangalore. Her Postdoctoral fellowship is from Harvard Medical School and MIT on the chemical biology of kinases for cancer therapeutics. In 2013 she joined as an assistant professor in the discipline of chemistry jointly with biological engineering. She works on developing novel therapeutics for cancer. Her research is multidisciplinary involving synthetic organic chemistry, Molecular & cell biology. She also collaborates extensively with structural biologists and medical oncologists to study the kinase of interest. Currently her group works in two different target oriented drug discovery projects, one targeting DNA damaging pathways in cancer especially on ATR/ATM, TLK kinases and the other on studying IMPDH as a novel target for H pylori infection.   Her long-term goal is to make affordable medicines for cancer. She is also a recipient of prestigious Ramanujan Fellowship from DST.

Selected Patents and Publications

  • COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTRO INTESTINAL & MICROBIAL INFECTIONS: United States application or PCT international application number 14/571,673, Date of publication: 16/12/2014. Lizbeth K Hedstrom, Gregory D Cuny, Deviprasad R Gollapalli, Sivapriya Kirubakaran, Boris Striepen, Suresh Kumar Gorla, Sushil K Maurya, Mandapati Kavitha.
  • Compounds for treating mammalian gastrointestinal microbial infections, European Patent Application EP2408753, Lizbeth K Hedstrom, Gregory D Cuny, Deviprasad R Gollapalli, Sivapriya Kirubakaran, Boris Striepen, Suresh Kumar Gorla, Sushil K Maurya, Corey Robert Johnson, Mandapati Kavitha, Jihan Khan, Publication date: 25/1/2012
  • Biochemical, Cellular and in vivo characterization of Torin2, an ATP-competitive mTOR, ATM and ATR inhibitor: Qingsong Liu*, Chunxiao Xu*, Sivapriya Kirubakaran, Xin Zhang, Wooyoung Hur, Yan Liu, Nicholas P. Kwaitkowski, Jinhua Wang, Kenneth Westover, Peng Gao, Dalian Erica,  Carson C. Thoreen, Seong A. Kang, Matthew P. Patricelli, Pasi A. Janne, Kwok Wong, David M. Sabatini, Nathanael S. Gray, Cancer Res. 2013, 73(8):2574-2586 ( * Equal first authors) Structure-activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH: Sivapriya Kirubakaran, Suresh Kumar Gorla, Lisa Sharling, Minjia Zhang, Xiaoping Liu, Soumya S. Ray, Iain S. MacPherson, Boris Striepen, Lizbeth Hedstrom and Gregory D. Cuny, Bioorg. Med. Chem. Lett., 22 (5), 2012, 1985–1988
  • Kinome-wide selectivity profiling of ATP-competitive mTOR (mammalian target of rapamycin) inhibitors and characterization of their binding kinetics: Liu Q , Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Z, Kang SA, Zhao J, Look AT, Sorger PK, Sabatini DM, Gray NS,  J Biol Chem. 2012, 287(13), 9742-52 Macpherson I, Kirubakaran S, et al: “The Structural Basis of Cryptosporidium-Specific IMP Dehydrogenase Inhibitor Selectivity”J. Am. Chem. Soc., 2010, 132 (4), 1230–1231).